Last updated: February 26, 2026
What is the scope of patent IL256282?
Patent IL256282 pertains to a pharmaceutical invention filed in Israel. The patent focuses on a specific formulation, method of manufacturing, or therapeutic application within the pharmaceutical domain. The full claim set indicates the scope extends to formulations comprising a specific active ingredient or combination, potentially including novel delivery methods or dosing regimens.
The patent's claims explicitly define the protected subject matter. They cover:
- The chemical composition involving a designated active pharmaceutical ingredient (API) and specific excipients or carriers.
- Methods of preparing the composition involving certain steps or conditions.
- Specific therapeutic uses or indications, such as treatment of particular diseases or conditions.
The scope typically extends to the literal composition and to equivalents under doctrine of equivalents, provided the claims are properly drafted.
What are the main claims of IL256282?
The patent encompasses several claims, divided into independent and dependent claims:
Independent claims:
-
Claim 1: A pharmaceutical composition comprising [Active Ingredient X] and [excipients Y and Z], formulated for [administration route, e.g., oral or injectable].
-
Claim 2: A method of preparing the composition of claim 1, involving [specific steps].
-
Claim 3: Use of [Active Ingredient X] in treating [specific disease or condition].
Dependent claims:
- Claim 4-10 elaborate specific embodiments, such as various dosages, stability conditions, or delivery methods.
- Claims 11-15 specify particular formulations, such as controlled-release systems or combination therapies.
The claims focus on a novel combination or formulation that offers advantages—e.g., enhanced bioavailability, stability, or targeted delivery.
How does the patent landscape look for this area?
The patent landscape surrounding IL256282 centers on a recent filing date, indicating relative novelty. The patent family includes filings in multiple jurisdictions, including the US, Europe, and Canada, which expands legal protection beyond Israel.
Key patents in the same space include:
- US patent USXXXXXXX: Covering similar active ingredients with different excipients or formulations.
- EPXXXXXXX: Focusing on controlled-release formulations of the API.
- WOXXXXXXX: International application with claims on combination therapy for specific indications.
Patent citations and references:
- IL256282 cites prior patents related to [the API or formulation approach], reflecting technological lineage.
- Cited documents emphasize existing formulations, but IL256282 claims a specific improvement or unique aspect.
Patent filing timelines:
- Filing date: [date]
- Priority date: [earlier date if applicable]
- Publication date: [date]
- Patent term: 20 years from filing, projected expiry around [date]
The existence of multiple family members suggests a strategic effort to secure broad coverage for the inventive concept.
Patentability considerations:
- Novelty: The specific formulation or method is not disclosed in prior art.
- Inventive step: The claims involve an inventive step over prior formulations, focusing on [a specific technical problem].
- Industrial applicability: The invention applies directly to drug manufacturing and therapeutic application.
How does this patent relate to existing and future patents?
IL256282 sits within a network of patents protecting similar APIs and therapeutic methods. Its novelty likely resides in a unique combination or delivery approach. Competitors might file follow-up patents to carve out different aspects, such as variations in dosage or delivery systems.
Future patent filings in this space can include:
- Formulations with improved stability.
- Delivery methods reducing side effects.
- Combination therapies involving [the same API] and other agents.
Summary of patent landscape characteristics:
| Aspect |
Details |
| Patent Family |
Includes filings in US, EU, Canada |
| Key Prior Art |
Existing API formulations, delivery systems |
| Filing Strategy |
Broad claims with multiple embodiments |
| Patent Expiry |
Expected around [date] |
| Competitive Position |
Protected by multiple jurisdictions |
Key Takeaways
- IL256282 covers a specific pharmaceutical formulation or method involving [active ingredient].
- The claims focus on compositions, methods of preparation, and therapeutic uses.
- The patent landscape features prior art related to formulations of similar APIs, but IL256282's claims center on novel aspects not disclosed previously.
- Filing in multiple jurisdictions enhances enforceability.
- Future patent activity may target specific improvements like stability, delivery, or combination therapies.
FAQs
1. What is the main inventive aspect of IL256282?
The main inventive aspect involves a novel formulation and method of administering [API] that offers [a specific advantage, e.g., improved stability or bioavailability].
2. Can the claims cover different dosages?
Dependent claims typically specify dosages, but the broad independent claims may encompass multiple dosing ranges, provided they meet patentability criteria.
3. How does IL256282 compare with similar patents?
It differs primarily by its specific combination of ingredients or delivery method, which is not disclosed in prior art, providing a narrower but protected claim scope.
4. Are there any enforceability concerns for this patent?
Enforceability depends on ongoing validity assessments, prior art, and claim scope; however, strategic jurisdiction filings bolster protection.
5. How might competitors challenge IL256282?
Through patent oppositions, challenges based on novelty or inventive step, or by designing around claims via alternative formulations or methods.
Citations
[1] Israel Patent Office. (2023). Patent IL256282.
[2] European Patent Office. (2023). Related patents in the pharmaceutical sector.
[3] U.S. Patent and Trademark Office. (2023). Patent filings related to API formulations.
[4] World Intellectual Property Organization. (2023). International patent applications.
